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the international faculty of 22 countries from Europe and the USA 
but also Asia-Pacific (table 1). The panel openly disclosed any po-
tential conflict of interest (COI) (www.oncoconferences.ch); the 
COI committee was once more chaired by Harold Burstein (Bos-
ton, USA). It was recognized as being unavoidable that individual 
panel members have financial relationships with commercial or-
ganizations engaged in research, innovation, and education. None 
of the declared conflicts were judged to substantially impact the 
voting procedure and warrant exclusion of a panel member. How-
ever, members with a specific COI were asked to refrain from vot-
ing at certain questions.
The motto of this year’s panel discussions and voting was: ‘Tai-
loring therapy: towards precision treatment of patients with early 
breast cancer’. About 3,500 participants from 135 countries saw 3 
days of high-level educational lectures addressing local and sys-
temic therapy as well as imaging issues. Interestingly, and against 
contrary trends of other disease-specific conferences, the number 
of participants increased compared to the previous meeting – likely 
also a consequence of the successful move to logistically easier to 
reach Vienna. Again, a large number of participants from overseas, 
particularly China, Japan, and the USA, attended and made the 
meeting the probably most important international breast cancer 
meeting on European soil from a global perspective.
The Saturday morning consensus panel was again co-chaired 
by Aaron Goldhirsch (CH/I) and Eric Winer (USA), who also 
moderated the discussion and voting. This time, more than 170 
questions had been developed and exchanged by panelists upfront, 
which reduced debate and put some time pressure on the panel in 
order to agree on solutions suitable for breast cancer care around 
the world. It was again stated that clinical trials provide evidence 
that shows whether one treatment is better than another and help 
to estimate an average of outcome improvement, but not how to 
treat a given individual patient. The primary consideration on 
which the panel’s voting decisions were based upon was to provide 
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Summary
The 2015 St. Gallen Consensus Conference on early 
breast cancer took place in Vienna, Austria, for the first 
time. After 3 days of high-level presentations by interna-
tional panel members of clinical trials having been re-
ported recently in the field, the traditional Saturday vot-
ing tried to translate the assembled knowledge into clini-
cal treatment recommendations intended to guide clini-
cal practice of breast cancer care for the ‘average’ 
patient. This report summarizes the results of the 2015 
international panel voting procedures with respect to lo-
coregional and endocrine treatment, chemotherapy, tar-
geted therapy, as well as adjuvant bisphosphonate use. 
This report is not aimed to replace the official St. Gallen 
consensus publication – some recommendations may 
even be altered in the final paper – but should serve as a 
preliminary rapid report of this important meeting.
Introduction
The St. Gallen Consensus Conference 2015 (March 18–11), held 
for the first time in Vienna, Austria, and now chaired by 7 co-
chairs, focused again on therapy recommendations for early breast 
cancer which are based on evidence as well as clinical expertise of 
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a treatment choice for women with early breast cancer by consid-
ering tumor biology and host factors, also balancing benefits and 
risks of therapies. 
The 2015 discussion now finally entirely incorporated a mod-
ern differentiation of breast cancer [1] including the concept of 
intrinsic biological subtypes but also of further molecular charac-
terization of the disease [2, 3]. Great emphasis was again given to 
locoregional treatment aspects, with observations that surgery is 
being further minimized but radiotherapy appears to be becoming 
more aggressive [4], and surgical tactics do not change much after 
neoadjuvant therapy. The impact of a rising number of molecular 
testing tools was assessed, both for judging prognosis of early and 
late metastasis risk, but also for prediction of therapy benefit. Par-
ticularly the benefit of extended endocrine therapy [5] and the 
current standard of care of endocrine therapies in young patients 
were extensively covered in light of recent pivotal trial result pres-
entations.
In general, the panelists were asked to cast their vote using 3 
possible answers allowed: Yes/No/Abstain. However, due to the 
complexity of some questions, more options were given in certain 
instances. ‘Abstain’ was to be used in the case of insufficient data, 
no personal expertise on the particular issue, or conflict of interest. 
After each vote, the answers were summarized in percentages. This 
report summarizes the original voting questions and resulting per-
centages of the St. Gallen panel discussion on Saturday March 11, 
2015. 
Surgery of the Primary Tumor
Locoregional treatment aspects were again a major topic of this 
year’s St. Gallen/Vienna Consensus: Despite extensive discussions, 
there were no major changes in technical aspects of primary tumor 
resection, but it can be noted the ‘margin issue’ appears now to be 
resolved and that oncoplastic techniques have found their role the 
field of breast-conserving surgery. Also, breast-conserving surgery 
was again confirmed as intended standard of care, also in cases of 
multifocal (72% Yes, 14% No, 14% Abstain) or multicentric (79% 
Yes, 21% No) disease, provided that clear margins can be achieved 
and whole-breast radiotherapy is planned.
When asked about the minimum acceptable surgical margin, 
92% of panelists voted for ‘no ink on invasive tumor’, and 8% for 
‘1–2 mm’ clearance. The panel was clear on whether the margin 
required should depend on tumor biology (100% No), should be 
greater when age is less than 40 years (100% No), should be greater 
for lobular histology (100% No), and should be greater after neoad-
juvant chemotherapy (90% No, 8% Yes, 2% Abstain). A clear ma-
jority of panelists felt that margins should not be greater in the 
presence of extensive intraductal component (80% No, 20% Yes) 
and greater for pure ductal carcinoma in situ than for invasive dis-
ease (80% No, 20% Yes).
After downstaging by neoadjuvant chemotherapy, the entire 
area of the original primary does not need to be resected (89% Yes, 
9% No, 2% Abstain). 
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Surgery of the Axilla
Sentinal node (SN) biopsy was once more confirmed as the 
standard of care [6]. The panel discussions focused on controver-
sial issues of axillary dissection (AD) after positive SN, defining 
that AD cannot be omitted in patients with positive SN if mastec-
tomy without radiotherapy was planned (100% No), but the panel 
was split on whether such omission would be appropriate for pa-
tients with mastectomy and radiotherapy (52% Yes, 48% No). The 
panel by majority voted that AD can be omitted after positive SN 
in breast conservation situations with radiotherapy using standard 
tangents (67% Yes, 33% No), and high tangents to include the 
lower axilla (94% Yes, 3% No, 2% Abstain).
After neoadjuvant chemotherapy and successful downstaging of 
an initially clinically positive axillary node, SN biopsy was consid-
ered an appropriate method (90% Yes, 7% No, 3% Abstain); how-
ever, the panel felt that AD should not be avoided if the SN turns 
out to be positive (10% Yes, 90% No).
Radiotherapy
The panel was split over the controversy of whether partial 
breast irradiation should be used as definitive irradiation for 
ASTRO (American Society for Radiation Oncology) / ESTRO (Eu-
ropean Society for Radiotherapy and Oncology)-‘suitable’ patients 
(49% Yes, 40% No, 11% Abstain), but declined this strategy for 
ASTRO/ESTRO-‘cautionary’ patients (2% Yes, 78% Yes, 22% Ab-
stain), and did not feel that ‘only in the absence of adverse tumor 
pathology’ it would make a difference (22% Yes, 60% No, 18% Yes).
With respect to hypofractionated breast irradiation after breast-
conserving surgery, the panel felt that this is appropriate for pa-
tients aged 50+ without chemotherapy or axillary involvement 
(89% Yes, 2% No, 9% Abstain), but also for patients younger than 
50 years (71% Yes, 2% No, 27% Abstain), with uncertainty about 
patients with prior chemotherapy or axillary lymph node involve-
ment (51% Yes, 18% No, 31% Abstain).
The panel’s vote was unequivocal that after breast-conserving 
surgery, radiation should include breast only in the case of a nega-
tive SN/axilla (100% Yes). For positive nodes and breast conserva-
tion, only 5% thought that breast-only radiotherapy would be suf-
ficient, with 50% voting that breast and regional nodes but not in-
ternal mammary nodes (IMN) should be irradiated, 30% voting 
for radiotherapy of breast, regional nodes and IMN, and 16% ab-
staining.
Postmastectomy radiotherapy (PMRT) should be standard of 
care for T3 (90% Yes, 10% No), N+ 1–3 with adverse pathology 
(87% Yes, 7% No, 7% Abstain), but not for all N+ 1–3 (32% Yes, 
64% No, 4% Abstain) nor N+ 1–3 at age < 40 years (51% Yes, 37% 
No, 12% Abstain). PMRT should be given to patients with positive 
SN but no AD (70% Yes, 17% No, 13% Abstain), but not to pN0 
patients after AD and < 8 nodes dissected (0% Yes, 95% No, 5% 
Abstain) unless micrometastases were found in the latter situation 
(71% Yes, 185 No, 11% Abstain).
A relative majority of panel members (41%) found that PMRT 
should include chest wall and regional nodes but not IMN (32% 
Abstain, 11% Chest wall only, 16% Chest wall and regional nodes 
and IMN). Radiotherapy after immediate reconstruction should 
include the reconstructed breast and nodes in most cases (55% Yes, 
29% No, 16% Abstain), with uncertainty about ‘only for tumors 
with adverse pathological features’ (37% Yes, 43% No, 20% Ab-
stain).
In general, the panel felt that after neoadjuvant therapy, radio-
therapy strategies should follow the stage before neaodjuvant ther-
apy (68% Yes, 22% No, 10% Abstain) rather than after neoadjuvant 
therapy (24% Yes, 66% No, 10% Abstain).
Pathology, Prognostic, and Predictive Factors
As in 2013 [7], the panel again agreed that distinction between 
‘luminal A-like’ and ‘luminal B-like’ (HER2-negative) can be de-
rived from estrogen receptor (ER), progesterone receptor, and 
Ki-67 status (78% Yes, 22% No), and that Ki-67 use requires 
knowledge of local laboratory values (70.3% Yes, 13.5% No). The 
minimum value of Ki-67 required for ‘luminal B-like’ was for the 
majority of the panel 20–29% (36.4%). About one fifth (20.5%) 
stated that Ki-67 should not be used for this distinction. The ma-
jority (66.7%) disagreed with the statement that only multigene 
classifiers (e.g. PAM50, MammaPrint®/Blueprint® (Agendia, Am-
sterdam, The Netherlands)) can appropriately determine molecu-
lar subtype; 59.5% disagreed with the statement that subtype does 
not need to be determined since it can be replaced by risk scores 
derived from multi-gene tests.
The vote was split with regard to the question of whether the 
extent of lymphocytic infiltration should be reported and used as a 
prognostic marker in triple-negative breast cancer (TNBC) and 
HER2-positive disease (45.2% Yes, 54.8% No). The majority disa-
greed with the extent of lymphocytic infiltration to be reported and 
used as a predictive marker (7.7% Yes, 89.7% No).
For the question of whether a chemotherapy decision in pa-
tients with ER-positive HER2-negative N0 breast cancer always re-
quires Ki-67 or multi-gene assays, the vote was split (55.6% Yes, 
44.4% No).
There were 3 questions on all multigene assays, addressing 
whether they are prognostic for short-term and long-term out-
come and whether they predict chemotherapy response. 
The Yes answers are summarized in table 2. 
Endocrine Therapy
Premenopausal
Surely affected by the recent data on ovarian function suppres-
sion (OFS) as adjuvant treatment option in premenopausal pa-
tients, a substantial part of the discussion was focused on this topic 
[8, 9]. Thus, the session on endocrine treatment began with a dis-
cussion of 2 cases. In case 1, recommendation of standard adjuvant 
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endocrine therapy for a 42-year-old patient with an intermediate 
grade (G2), node-negative, steroid hormone receptor-positive 
breast cancer, having not received adjuvant chemotherapy, was 
discussed. The majority of the panelists (85.0%) voted for treat-
ment with tamoxifen alone, 12.5% for OFS plus tamoxifen. In a 
second case, the panelists were asked to vote on adjuvant endo-
crine treatment of a 34-year-old patient who remained premeno-
pausal after adjuvant chemotherapy for a pT1, grade 3, node-posi-
tive steroid hormone receptor-positive breast cancer. The majority 
would treat her with OFS and exemestane (69.8%), a minority 
(23.3%) with OFS and tamoxifen. Only a few panelists voted for 
tamoxifen (2.3%) alone or abstained. 
Then, general recommendations of the indication of OFS were 
discussed. Most panelists voted for considering age   35 years 
(81%), premenopausal estrogen levels after chemotherapy (73.7%), 
and high tumor load (4 or more axillary lymph nodes; 89.7%) as 
arguments in favor of OFS. Unfavorable biology, i.e. grade 3 
(55.9% Yes, 38.2% No) or adverse result of multi-gene test (60% 
Yes, 24.4% No), was less clearly judged as argument in favor of 
OFS. Then, more explicitly, the preference of OFS plus an aro-
matase inhibitor (AI) rather than OFS and tamoxifen was dis-
cussed. The strongest arguments in favor of using AI were grade 3 
(92.5%) and high tumor load (4 or more axillary lymph nodes; 
92.5%), followed by adverse result of multi-gene test (65.8%) and 
age   35 years (59.4% Yes, 37.5% No). Some more panelists felt 
that premenopausal estrogen level after adjuvant chemotherapy 
should not be an argument in favor of the use of AI in combination 
with OFS (51.2% Yes, 43.9% No). In order to give a clear recom-
mendation as to the preferred combination if OFS seems to be nec-
essary, the panel was also asked for general preference between ta-
moxifen and AI; the majority (58.5%) voted for recommending the 
combination of AI with OFS, only 36.6% considered tamoxifen 
plus OFS as treatment of choice.
Postmenopausal
Tamoxifen was still considered as adequate treatment in some 
postmenopausal patients (97.6%); however, clear factors arguing 
for inclusion of an AI were high tumor load defined by 4 or more 
tumor-infiltrated axillary lymph nodes (97.6%), or unfavorable bi-
ology defined by grade 3 or high Ki-67 (97.7%), or HER2 positivity 
(71.1%). Age (> 60 years) was not considered as an argument for 
AI inclusion (31% Yes, 69% No).
With regard to the sequence of AI and tamoxifen, a slight ma-
jority declined to start AI upfront in all patients (47.5% Yes, 52.5% 
No); however, in patients at higher risk, upfront AI was clearly re-
garded as the preferred mode of therapy (95.5% Yes). According to 
the vote of the panelists (75.0%), upfront AI can be switched to ta-
moxifen after 2 years. 
Duration
Recent publications studied prolongation of the adjuvant endo-
crine treatment exceeding the traditional duration of 5 years, and 
the results suggested advantages in some patients [10–12]. In a de-
tailed discussion, votes on several scenarios were performed.
In patients with node-positive disease who are disease-free after 
5 years of tamoxifen, a vast majority of the panelists would recom-
mend continuing AI / AI/OFS or tamoxifen up to 10 years (pre-
menopausal 100%, postmenopausal 95.2%). For patients with 
node-negative disease, most panelists voted against prolongation 
(premenopausal 74.4%, postmenopausal 80.5%). However, in pa-
tients with grade 3 or high Ki-67, the majority would advise pro-
longation of endocrine therapy (premenopausal 73.8%, postmeno-
pausal 76.7%).
Finally, for those postmenopausal patients who were premeno-
pausal at baseline, a majority of panelists (66.7%) would recom-
mend a prolongation of endocrine therapy, presumably triggered 
by the subgroup analysis of the MA.17 trial that showed particular 
benefit of letrozole after 5 years tamoxifen in these patients [12]. 
With regard to the details of the specific treatment in the case of 
an indication for endocrine therapy beyond the first 5 years, the 
discussion had the following results: After 5 years of adjuvant ther-
apy involving switch from tamoxifen to an AI (therefore assuming 
postmenopausal status at the 5-year time point and reasonable tol-
erance to endocrine therapy), most panelists voted to recommend 
continuation of AI to a cumulative total of 5 years (75.0%). A fur-
ther 5 years of pure tamoxifen or AI treatment was supported only 
by a minority (tamoxifen 39.4%, AI 31.4%). Finally, the voting was 
focused on treatment recommendations after 5 years of straight AI 
adjuvant therapy; although some panelists (40.9% Yes) voted in 
favor of further prolongation of adjuvant endocrine therapy (ta-
moxifen or AI), the majority thought that 5 years of AI would be 
sufficient and voted not to recommend further endocrine therapy 
(tamoxifen 63.4% No; AI 57.1% No). However, being asked for a 
specific recommendation in a patient with moderate risk of recur-
rence and tolerating the endocrine treatment, the answers of the 
panelists were even less clear-cut between 3–5 years of tamoxifen 












85 81 93 70 58
Long-term  
outcome
44 15 63 38 31
Chemotherapy  
response
81 35 38 24 10
Table 2. ‘Yes’ votes for multigenomic assays
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The voting on the optimal duration of OFS in a premenopausal 
woman for whom this treatment is indicated was rather unambigu-
ous; most panelist (56.7%) recommended 5 years or even life-long 
(3.3%), a minority (16.7%) voted for a shorter period of 2–3 years, 
and a substantial proportion abstained (23.3%). 
Chemotherapy
The panel voted that the following factors constituted relative 
indications for the inclusion of adjuvant chemotherapy: Histologi-
cal grade 3 tumor (97.4% Yes); any positive node (38.7% Yes); 4 or 
more positive nodes (95.1% Yes); high Ki-67 (75.0% Yes); age < 35 
years (41.7% Yes); extensive lymphovascular invasion (67.6% Yes); 
low hormone receptor staining (81.1% Yes).
The majority agreed that luminal A phenotype needs to be con-
sidered as less responsive to chemotherapy (88.1% Yes). Regarding 
risk factors indicating use of chemotherapy in luminal A, the panel 
voted for the following factors: Tumor size (36.4% Yes, 63.2% ab-
stained when asked about a minimum size); lymphovascular inva-
sion (28.6% Yes); 1–3 involved nodes (34.9% Yes);   4 involved 
nodes (91.1% Yes).
The majority did not think that in IHC-luminal B-like tumors 
chemotherapy should be recommended in all patients (22.0% Yes), 
but rather only in patients with other indicators of increased risk 
(87.5% Yes). In patients with luminal B-like disease and a low On-
cotype Dx® (Genomic Health, Inc. Redwood City, CA, USA) score 
(94.9% Yes) but not an intermediate score (36.4% Yes), chemother-
apy may be omitted. Chemotherapy may also be omitted in pa-
tients with a low-risk Mammaprint result (72.1% Yes), a low 
PAM50 risk of recurrence score (82.5% Yes), and a low-risk Endo-
Predict® (Sividon, Köln, Germany) result (69.6% Yes).
In luminal B (HER2-negative) tumors, chemotherapy should 
include an anthracycline (83.3% Yes) and a taxane (76.9% Yes). 
The panel stated that 6 cycles of the same chemotherapy, such as 
6× AC (cyclophosphamide, doxorubicin) or 6× FEC (fluorouracil, 
epirubicin, cyclophosphamide), should not be given anymore 
(21.6% Yes). 57.1% believed that there was a high-risk group for 
which dose-dense chemotherapy should be preferred.
In TNBC, chemotherapy should contain anthracyclines and 
taxanes (92.3% Yes). Only 7.1% believed a platinum-based regimen 
should be considered in all TNBC patients. The majority (57.9%) 
would consider a platinum-based regimen only in known BRCA 
mutation carriers. Nevertheless, the majority (75%) also thought 
that a standard anthracycline- and taxane-containing regimen is 
still acceptable in TNBC with BRCA mutation. Only 45% thought 
that dose-dense chemotherapy requiring growth factor support 
should be preferred in TNBC.
In HER2-positive disease, 97% believed chemotherapy should 
always be given to patients with stage 2 disease who require anti-
HER2 therapy. 88.9% believed that this chemotherapy should 
contain anthracyclines, and 97.2% believed that it should contain 
taxanes. 97.3% agreed that the anti-HER2 therapy should start 
concurrent with the taxane. In patients with HER2 positivity ac-
cording to American Society of Clinical Oncology (ASCO)/Col-
lege of American Pathologists (CAP) guidelines, the panel voted 
for anti-HER2 therapy in stage 1 disease in T1a (20.7% Yes), T1b 
(81.4% Yes), and T1c (100%). Here, only 57.9% thought that the 
chemotherapy should contain anthracyclines (57.9%), and 86.5% 
agreed that paclitaxel and trastuzumab would be a reasonable 
option. 
For patients requiring adjuvant anti-HER2 therapy for a T2 
tumor with 4 involved nodes, only 21.4% thought that therapy 
should include both trastuzumab and pertuzumab, and only 8% 
thought that it should contain both trastuzumab and lapatinib.
Among neoadjuvant therapy choices for HER2-positive stage II 
disease, 23.1% considered taxane, trastuzumab and pertuzumab, 
and 56.4% anthracycline taxane + anti-HER2 an acceptable regi-
men. If asked whether taxane, trastuzumab, and pertuzumab is an 
acceptable neoadjuvant regimen for HER2-positive stage II disease, 
73.1% agreed and only 39.3% considered platinum, taxane, trastu-
zumab ± pertuzumab as an acceptable regimen. A non-taxane regi-
men containing platinum, trastuzumab ± pertuzumab only got 
2.9% Yes votes whereas anthracycline taxane and anti-HER2 got 
97.2% Yes votes. 
For stage II TNBC, only 17.2% thought that the preferred neo-
adjuvant regimen should include a high-dose alkylating agent, 
25% that it should include a platinum compound, and 94.7% that 
it should contain anthracycline taxane. Only 22.9% voted for 
nab-paclitaxel EC (epirubicin, cyclophosphamide), and 25.7% 
for an anthracycline regimen with alkylating agents (e.g. classical 
CMF (cyclophosphamide, methotrexate, fluorouracil)) in this 
context. 
73.5% believed that neoadjuvant cytotoxic therapy should be 
discussed as an option in patients with ‘luminal A-like’ tumors 
only if conservative surgery would not otherwise be feasible. Yet, 
only 16% believed neoadjuvant cytotoxic therapy should be dis-
cussed as an option in patients with ‘luminal A-like’ tumors. 
87.9% considered neoadjuvant endocrine therapy without cyto-
toxics a reasonable option for postmenopausal patients with endo-
crine responsive disease. 42.9% considered 4–8 months as an opti-
mal therapy duration, and 42.9% favored therapy until best re-
sponse. 
Bisphosphonates
For the first time, a majority of the panel voted that adjuvant 
bisphosphonates, such as zoledronic acid every 6 months or oral 
clodronate, are indicated during adjuvant endocrine therapy for 
postmenopausal patients with endocrine responsive disease 
(58% Yes, 42% No). The panel was split on premenopausal pa-
tients receiving luteinizing hormone-releasing hormone 
(LHRH) plus tamoxifen (44% Yes, 56% No), but clear that bis-
phosphonates should not be used for premenopausal patients 
not receiving LHRH (5% Yes, 95% No) and that denosumab 
should not be a substitute for bisphosphonates (4% Yes, 89% 
No, 7% Abstain).
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Special Issues and Patient Populations
For elderly patients, the panel was very clear that for standard 
chemotherapy there is no absolute age limit, rather disease factors, 
co-morbidities, life expectancy, and patient preferences shall be 
factors in the decision (87%). As for radiotherapy in elderly pa-
tients, 30% of panel members felt that it should be omitted over the 
age of 70 years after breast conservation in ER-positive tumors, but 
56% felt that the same multifactorial approach as described above 
should be taken.
For young patients, a majority of the panel felt that all patients 
younger than 40 years should be tested for BRCA 1 and 2 (73% 
Yes, 24% No, 3% Abstain). For patients with TNBC, BRCA testing 
should be done in all patients < 40 years of age (91% Yes, 6% No, 
3% Abstain) but not all patients < 60 years of age (49% Yes, 49% 
No, 2% Abstain).
The majority of the panel felt that discovery of a BRCA 1 or 2 
mutation influences the treatment strategy with respect to the lo-
coregional (78% Yes, 22% No) or neoadjuvant (66% Yes, 35% No) 
but not adjuvant strategy (29% Yes, 66% No, 5% Abstain).
Only a minority of the panel felt that all breast cancer patients 
(11% Yes), or patients < 40 years of age (41% Yes, 50% No) should 
be tested for high-risk mutations of other genes. However, such 
testing should be done for patients with a strong family history 
(95% Yes), or age < 35 years at diagnosis (89% Yes), or age < 50 
years in ER-/HER2-negative tumors (70% Yes, 30% No). The panel 
was split on this question in patients with basal-like tumors (49% 
Yes, 46% No, 5% Abstain).
The panel was clear that fertility preservation should be offered 
to women < 40 years of age (88% Yes, 10% No, 2% Abstain), as well 
as OFS during chemotherapy in receptor-negative disease (79% 
Yes, 18% No, 3% Abstain).
For breast cancer diagnosed during pregnancy, the panel voted 
that premature delivery should be avoided if possible (89% Yes, 4% 
No, 7% Abstain), breast conservation is a suitable option (89% Yes, 
3% No, 8% Abstain), lymphoscintigraphy and SN biopsy are safe 
(65% Yes, 29% No, 6% Abstain), and anti-HER2 therapy should be 
delayed until after delivery (87% Yes, 8% No, 5% Abstain). However, 
the panel was unclear about immediate postmastectomy reconstruc-
tion as an appropriate option (53% Yes, 39% No, 10% Abstain).
With respect to attempting pregnancy after breast cancer, the 
panel felt that it is reasonable to interrupt endocrine therapy after 
18–30 months (61% Yes, 30% No, 9% Abstain) and only in the ab-
sence of high-risk factors (61% Yes, 28% No, 11% Abstain), but not at 
any time during endocrine therapy (26% Yes, 68% No, 6% Abstain).
For endocrine-responsive male breast cancer, the panel felt that 
tamoxifen should be recommended, but not AI (29% Yes, 58% No, 
13% Abstain) nor AI + LHRH (30% Yes, 67% No, 3% Abstain).
With respect to diet and exercise after breast cancer, the panel 
did not recommend specific dietary advice (40% Yes, 58% No, 2% 
Abstain), but favored vitamin D supplementation for vitamin D-
deficient patients (57% Yes, 34% No, 9% Abstain) and exercise 
regimens as standard of care (77% Yes, 23% No), and recom-
mended weight loss/avoidance of weight gain (88% Yes, 8% No, 5% 
Abstain).
Conclusion
In summary, St. Gallen/Vienna 2015 was a highly successful 
conference. International attendance increased as compared to the 
previous meeting, and the panel conquered a record number of al-
most 200 questions, likely because of excellent iterative preparation 
of the questions in the months and weeks preceding the confer-
ence. Overall, recommendations were further moving toward the 
‘biology of the disease’, with increasing attention to host factors 
and special patient populations. This reflects the way the field is 
moving forward in terms of gathering knowledge, and will be help-
ful in many difficult or conflicting treatment decision situations. 
Based on experience and opinion by distinguished international 
experts rather than on systematic evidence, the results may differ 
from national [13] or international guidelines, but will still be an 
important source of advice for many physicians and patients.
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